Literature DB >> 33669071

Overview of Synthetic Cannabinoids ADB-FUBINACA and AMB-FUBINACA: Clinical, Analytical, and Forensic Implications.

Carolina Lobato-Freitas1, Andreia Machado Brito-da-Costa2, Ricardo Jorge Dinis-Oliveira1,2,3, Helena Carmo1, Félix Carvalho1, João Pedro Silva1, Diana Dias-da-Silva1,2.   

Abstract

ADB-FUBINACA and AMB-FUBINACA are two synthetic indazole-derived cannabinoid receptor agonists, up to 140- and 85-fold more potent, respectively, than trans-∆9-tetrahydrocannabinol (∆9-THC), the main psychoactive compound of cannabis. Synthesised in 2009 as a pharmaceutical drug candidate, the recreational use of ADB-FUBINACA was first reported in 2013 in Japan, with fatal cases being described in 2015. ADB-FUBINACA is one of the most apprehended and consumed synthetic cannabinoid (SC), following AMB-FUBINACA, which emerged in 2014 as a drug of abuse and has since been responsible for several intoxication and death outbreaks. Here, we critically review the physicochemical properties, detection methods, prevalence, biological effects, pharmacodynamics and pharmacokinetics of both drugs. When smoked, these SCs produce almost immediate effects (about 10 to 15 s after use) that last up to 60 min. They are rapidly and extensively metabolised, being the O-demethylated metabolite of AMB-FUBINACA, 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamide)-3-methylbutanoic acid, the main excreted in urine, while for ADB-FUBINACA the main biomarkers are the hydroxdimethylpropyl ADB-FUBINACA, hydroxydehydrodimethylpropyl ADB-FUBINACA and hydroxylindazole ADB-FUBINACA. ADB-FUBINACA and AMB-FUBINACA display full agonism of the CB1 receptor, this being responsible for their cardiovascular and neurological effects (e.g., altered perception, agitation, anxiety, paranoia, hallucinations, loss of consciousness and memory, chest pain, hypertension, tachycardia, seizures). This review highlights the urgent requirement for additional studies on the toxicokinetic properties of AMB-FUBINACA and ADB-FUBINACA, as this is imperative to improve the methods for detecting and quantifying these drugs and to determine the best exposure markers in the various biological matrices. Furthermore, it stresses the need for clinicians and pathologists involved in the management of these intoxications to describe their findings in the scientific literature, thus assisting in the risk assessment and treatment of the harmful effects of these drugs in future medical and forensic investigations.

Entities:  

Keywords:  intoxication; metabolism; psychoactive substances; synthetic cannabinoids (SCs); toxicity

Year:  2021        PMID: 33669071      PMCID: PMC7996508          DOI: 10.3390/ph14030186

Source DB:  PubMed          Journal:  Pharmaceuticals (Basel)        ISSN: 1424-8247


  77 in total

1.  Fatal intoxication with new synthetic cannabinoids AMB-FUBINACA and EMB-FUBINACA.

Authors:  Piotr Adamowicz; Ewa Meissner; Marta Maślanka
Journal:  Clin Toxicol (Phila)       Date:  2019-02-26       Impact factor: 4.467

Review 2.  Spicing Up Pharmacology: A Review of Synthetic Cannabinoids From Structure to Adverse Events.

Authors:  Colin Davidson; Jolanta Opacka-Juffry; Angel Arevalo-Martin; Daniel Garcia-Ovejero; Eduardo Molina-Holgado; Francisco Molina-Holgado
Journal:  Adv Pharmacol       Date:  2017-06-20

3.  Pyrolysis of UR-144, a synthetic cannabinoid, augments an affinity to human CB1 receptor and cannabimimetic effects in mice.

Authors:  Asuka Kaizaki-Mitsumoto; Kyoko Hataoka; Masahiko Funada; Yuki Odanaka; Hiroki Kumamoto; Satoshi Numazawa
Journal:  J Toxicol Sci       Date:  2017       Impact factor: 2.196

4.  Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA.

Authors:  Samuel D Banister; Michael Moir; Jordyn Stuart; Richard C Kevin; Katie E Wood; Mitchell Longworth; Shane M Wilkinson; Corinne Beinat; Alexandra S Buchanan; Michelle Glass; Mark Connor; Iain S McGregor; Michael Kassiou
Journal:  ACS Chem Neurosci       Date:  2015-07-17       Impact factor: 4.418

5.  Synthetic Cannabinoid Abuse Resulting in ST-Segment Elevation Myocardial Infarction Requiring Percutaneous Coronary Intervention.

Authors:  Richard J Hamilton; Vadim Keyfes; Sahil S Banka
Journal:  J Emerg Med       Date:  2016-10-19       Impact factor: 1.484

Review 6.  Epoxides--is there a human health problem?

Authors:  M M Manson
Journal:  Br J Ind Med       Date:  1980-11

Review 7.  The Multiple Waves of Cannabinoid 1 Receptor Signaling.

Authors:  Carlos Nogueras-Ortiz; Guillermo A Yudowski
Journal:  Mol Pharmacol       Date:  2016-06-23       Impact factor: 4.436

8.  Assessment of types of synthetic cannabinoids in narcotic cases assessed by the Council of Forensic Medicine between 2011-2015, Ankara, Turkey.

Authors:  Ersin Göl; İsmet Çok
Journal:  Forensic Sci Int       Date:  2017-10-04       Impact factor: 2.395

9.  Evaluation of carboxamide-type synthetic cannabinoids as CB1/CB2 receptor agonists: difference between the enantiomers.

Authors:  Takahiro Doi; Takaomi Tagami; Akihiro Takeda; Akiko Asada; Yoshiyuki Sawabe
Journal:  Forensic Toxicol       Date:  2017-08-04       Impact factor: 4.096

10.  In vitro and in vivo pharmacokinetics and metabolism of synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA.

Authors:  Richard C Kevin; Timothy W Lefever; Rodney W Snyder; Purvi R Patel; Timothy R Fennell; Jenny L Wiley; Iain S McGregor; Brian F Thomas
Journal:  Forensic Toxicol       Date:  2017-03-10       Impact factor: 4.096

View more
  2 in total

1.  In-depth comparison of the metabolic and pharmacokinetic behaviour of the structurally related synthetic cannabinoids AMB-FUBINACA and AMB-CHMICA in rats.

Authors:  David Fabregat-Safont; María Mata-Pesquera; Manuela Barneo-Muñoz; Ferran Martinez-Garcia; Marie Mardal; Anders B Davidsen; Juan V Sancho; Félix Hernández; María Ibáñez
Journal:  Commun Biol       Date:  2022-02-24

2.  Adulteration of low-delta-9-tetrahydrocannabinol products with synthetic cannabinoids: Results from drug checking services.

Authors:  Manuela Carla Monti; Jill Zeugin; Konrad Koch; Natasa Milenkovic; Eva Scheurer; Katja Mercer-Chalmers-Bender
Journal:  Drug Test Anal       Date:  2022-02-02       Impact factor: 3.234

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.